Nestlé is developing AI-driven protein, collagen, and nutrient products specifically for people using GLP-1 weight-loss medications [1].
The move represents a strategic pivot for the food giant. As drugs like Ozempic and Wegovy reduce appetite and change how people eat, Nestlé is attempting to turn a potential decline in food consumption into a new commercial market.
These medications can cause nutritional deficiencies and dull the sense of taste in some users [3]. To counter these effects, Nestlé is utilizing its research and development facilities to create specialized nutrition lines. The company is also tweaking existing food recipes to better appeal to the altered palates of those on GLP-1 therapies [3].
The target market includes millions of consumers taking these medicines globally [1]. By focusing on high-protein and collagen-rich options, the company aims to help users maintain muscle mass and overall health while on calorie-restricted regimens.
Nestlé is integrating artificial intelligence into the development process to accelerate the creation of these nutrient-dense products [1]. This AI-driven approach allows the company to analyze nutritional needs and flavor profiles more efficiently as the pharmaceutical landscape shifts.
Industry analysts previously viewed the rise of GLP-1 drugs as a threat to the processed food industry. However, Nestlé is positioning itself to serve the specific dietary requirements that emerge after a patient begins medication [2].
“Nestlé is developing AI-driven protein, collagen, and nutrient products specifically for people using GLP-1 weight-loss medications.”
This strategy signals a broader shift in the food industry as pharmaceutical interventions for obesity become mainstream. By moving from general food production to targeted 'companion nutrition,' Nestlé is acknowledging that GLP-1 drugs permanently alter consumer behavior and biological needs, necessitating a new category of functional foods designed for medical users.
